Modern Medicines Series
SGLT2 Inhibitors: What we need to know
Over the first 3 programmes, Professor Cliff Bailey and colleagues provided concise evidence-based guidance to assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications. To watch these programmes on-demand please click here
Tuesday 14th December, 19:00 hours
SGLT2 Inhibitors: A 2021 update
Presenters: Professor Cliff Bailey & Dr Martin Hadley-Brown
A quick ‘bite-size’ update on SGLT2 Inhibitors from the 2021 major congresses. Prof Bailey will provide a quick revision of where we are before updating us on the latest CVD and renal developments while Dr Martin Hadley-Brown will join for the interactive audience discussion to answer questions from a primary care practicality point of view.
These webinars are supported by Boehringer Ingelheim through an unrestricted educational grant:
The content, opinions and statements made in these webinars are those of the presenters and do not necessarily reflect the views of the supporters, editors or editorial board and no liability is accepted for the consequences of any misleading or inaccurate information.